Periostin promotes chemoresistance to cisplatin and 5-FU in gastric cancer cells through the Akt/p53 pathway [44] and enhances gemcitabine resistance in pancreatic cancer through the Akt/ERK pathway [45]. Here, TP53 is linked to pancreatic neoplasm.